Supernus Pharmaceuticals Inc (SUPN)

32.58
0.63 1.90
NASDAQ : Health Care
Prev Close 33.20
Open 33.30
Day Low/High 32.10 / 33.30
52 Wk Low/High 9.51 / 23.30
Volume 291.73K
Avg Volume 568.20K
Exchange NASDAQ
Shares Outstanding 50.16M
Market Cap 1.67B
EPS 1.80
P/E Ratio 18.89
Div & Yield N.A. (N.A)

Latest News

Supernus Receives Final FDA Approval For Trokendi XR® For Migraine Prophylaxis In Adults And Adolescents

Supernus Receives Final FDA Approval For Trokendi XR® For Migraine Prophylaxis In Adults And Adolescents

Trokendi XR is the Leading Extended-Release Topiramate Product and Brand of Topiramate

Market Goes on a 'Buy the Dip' Trip

Market Goes on a 'Buy the Dip' Trip

Stocks slowly recovering from early lows.

There's No Rush for the Exits So Far

There's No Rush for the Exits So Far

There's lots of negativity, but dip buyers are showing up.

Shark Bites: Even Without Health Care Vote, Market's Feeling Better

Shark Bites: Even Without Health Care Vote, Market's Feeling Better

Broad strength and good tone mark action.

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.

The Bulls Don't Have Enough Juice for 20,000

The Bulls Don't Have Enough Juice for 20,000

But here are 8 stocks that look good to me, right now.

Rev's Forum: Can the Market Find a Second Wind?

Rev's Forum: Can the Market Find a Second Wind?

This is the time of the year when many moves are made for tax reasons.

Big-Cap Tech Names, Biotechs, Oils Lifting Market

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The number of new 12-month highs has climbed to 240.

Supernus Wins Appeal Case On Oxtellar XR®

Supernus Wins Appeal Case On Oxtellar XR®

U.S. Court of Appeals Affirms District Court's Decision on Oxtellar XR®

Supernus Provides Business Update

Supernus Provides Business Update

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

'Mad Money' Lightning Round: 'Health Care Is All Over the Map'

Jim Cramer urges caution with phamaceutical companies Supernus and Ariad

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer's 'Mad Money' Recap: Markets Pivot From Shocked to Bullish

Jim Cramer explains the rotation, looks ahead to next week.

Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA

Supernus Pharmaceuticals (SUPN) Shares Cross Below 200 DMA

In trading on Thursday, shares of Supernus Pharmaceuticals Inc crossed below their 200 day moving average of $18.67, changing hands as low as $18.00 per share. Supernus Pharmaceuticals Inc shares are currently trading off about 8.3% on the day.

Relative Strength Alert For Supernus Pharmaceuticals

Relative Strength Alert For Supernus Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.